Etizolam, an Anti-anxiety Agent, Attenuates Recurrence of Chronic Subdural Hematoma. Evaluation by Computed Tomography.

Abstract

Etizolam, an anti-anxiety agent which is an antagonist of platelet-activating factor receptors, was administered to patients with chronic subdural hematoma (CSH) after hematoma removal to assess the effectiveness for preventing recurrence compared with control patients not given the drug after surgery. The remaining volumes of subdural hematomas on brain computed tomography were measured approximately 1 month after removal. Volume in the etizolam group (15 patients) was significantly smaller than in the control group (24 patients). Hematoma recurrence was not detected in the etizolam group 3 months after surgery, but occurred in the control group. The difference was significant. Etizolam administration may be useful for the prevention of recurrence of CSH.

Effect of Platelet-Activating Factor Receptor Antagonist, Etizolam, on Resolution of Chronic Subdural Hematoma-A Prospective Study to Investigate Use as Conservative Therapy-

“…Our previous preliminary study revealed that administration of etizolam attenuated recurrence after surgery for CSDH, and that the remaining volume of hematoma 1 month after sur-gery was significantly smaller in the etizolam group than in the control group. 9) In the present study, etizolam administration and low density of hematoma on CT were found to be independent predictors for resolution without surgery, whereas hemiparesis as an initial symptom was an independent predictor for requirement for surgery. The initial symptoms of spontaneous resolution of CSDH are usually described as mild, such as headache and decrease in cognitive level.…”

“…7,8) Our recent prospective study showed that etizolam, a PAF receptor antagonist, attenuates the recurrence of CSDH after hematoma evacuation and irrigation. 9) The present study examined whether oral administration of etizolam decreased the requirement for surgery and identified the predictive factors.…”

Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons

“…CV 3988 partially rescues neurons from PAFR-dependent apoptosis resulting from C 18 -PAF signal transduction, consistent with its PAFR specificity; however, CV 3988 has no impact on PAF signaling in the absence of PAFR, regardless of the PAF isoform present. These data may help explain the mixed success of single PAF antagonists in therapeutic intervention (43)(44)(45)(46)(47)(48). We were surprised to see that PAFR antagonism had no impact on the survival of PAFR 1/1 neurons treated with C 16 -PAF, inasmuch as we have previously reported pro-apoptotic activity in nonneuronal PC12 cells (18).…”

Endovascular embolization of the left middle meningеal artery for residual chronic subdural hematoma (clinical case)

“…Рекомендаций по лечению резидуальных ХСГ в научной литературе мы не нашли. Опубликованы результаты исследований применения пероральных препаратов (транексамовой кислоты [3], периндоприла [4], этизолама [5], аторвастатина [6], стрептокиназы-стрептодорназы [7]), парентерального введения стероидных гормонов [8], гипергидратации [1] обСуждение Первые сообщения о лечении рецидивных ХСГ путем эмболизации средней оболочечной артерии относятся к 2013 г. [9].…”